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A major goal of the worldwide malaria eradication program is the reduction and eventual elimination of
malaria transmission. All currently available antimalarial compounds were discovered on the basis of their
activity against the asexually reproducing red blood cell stages of the parasite, which are responsible for the
morbidity and mortality of human malaria. Resistance against these compounds is widespread, and there is an
urgent need for novel approaches to reduce the emergence of resistance to new antimalarials as they are
introduced. We have established and validated the first high-throughput assay targeting the red blood cell
parasite stage required for transmission, the sexually reproducing gametocyte. This assay will permit
identification of compounds specifically targeting the transmission stages in addition to the asexual stage
parasites. Such stage-specific compounds may be used in a combination therapy, reducing the emergence of
resistance by blocking transmission of resistant parasites that may be selected in a patient.
Efforts for the development of vaccines and antimalarial
drugs have traditionally targeted asexual stages of
Plasmodium falciparum while virtually neglecting
transmission stages. Asexual stages are the proliferative
stages (generation time is 48 h) during the parasite
cycle in the human host, and organisms in this stage can
infect up to 20% of red blood cells (RBCs) in the body.
Current evidence suggests that a small subset of late
asexual RBC stages convert into sexually committed
schizont stages [1]. After invasion of an RBC, the
invasive daughter cells develop into male and female
sexual stage parasites, termed gametocytes, which
undergo fertilization after transmission to a mosquito
vector. Although the molecular mechanisms leading to
sexual conversion in vivo have not been characterized,
it is assumed that multiple external stimuli activate
a signaling cascade that feeds into some as-yet unknown
master regulator determining the ratio of asexual versus
sexual stages. After invasion of sexually committed
parasites into RBCs, parasites differentiate into mature
gametocytes over the course of 8–10 days.
The emergence of resistance against all currently used
drugs and unsuccessful attempts to develop vaccines
based on asexual blood stage antigens highlight the
importance of targeting transmission stages. Indeed, the
global campaign to eradicate malaria, initiated by
The Bill and Melinda Gates Foundation in 2007, has
recognized that inhibiting transmission needs to be
a top priority in the eradication effort. In addition to
a major focus on insecticide research, drugs and vaccines
designed to block transmission of malaria from an
infected person by killing or preventing maturation of
the sexual form of the parasite are key new approaches.
Current transmission blocking vaccine strategies
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are designed to induce human antibodies targeted
against parasite antigens expressed during the early development
of mosquito-stage parasites, thereby effectively blocking parasite
development. Naturally acquired transmission-blocking immu-
nity by this mechanism is well described (eg, in [2]). Alterna-
tively, transmission-blocking strategies could be based on
treating infected individuals with small molecules that inhibit
sexual stage parasite development in the human host. To date,
because of the technical difficulties in studying this stage, min-
imal effort has been invested in the development of drugs spe-
cifically active against transmission stages. Although artemisinin
combination therapies can reduce transmission, other treat-
ments are less effective. For example, sulphadoxine-pyrimeth-
amine can increase the fraction of gametocytes in patients with
malaria [3]. In addition, mature transmission stages are re-
fractory to most antimalarial compounds [4]. Development of
novel agents that work against transmission stages has been
hindered by lack of an assay that would allow large-scale com-
pound screening against sexual stages. This lack has been due to
difficulties in achieving reproducible sexual conversion rates in
vitro and to a lack of tools for the detection and quantification of
individual gametocyte stages. The aim of this study is to over-
come these experimental limitations through establishment of an
in vitro assay for sexual conversion and early development with
high-throughput capacity. We chose a whole cell assay to ensure
that potential hits have at least minimal drug-like properties and
acceptable solubility and cell permeability.
MATERIAL AND METHODS
P. falciparum In Vitro Culture
The gametocyte-producing 3D7 parasite strain, the P2G12 clone
and transgenic parasites derived from this clone were cultured in
vitro essentially as described elsewhere [5]. Parasites were
maintained in fresh type 01 human erythrocytes (Research
Blood Components) suspended at 4% hematocrit in complete
medium containing 1% (w/v) AlbuMAX II (Invitrogen), 0.5 mL
of gentamycin, 5.94 g of HEPES, 2.01 g of sodium bicarbonate,
0.05 g of hypoxanthine, and 10.44 g Roswell Park Memorial
Institute 1640 per liter at a pH of 6.74. Cultures were kept in
a controlled environment at 37C in a gassed chamber at 5%
CO2 and 1% O2.
Plasmid Construction and Generation of Transgenic Parasite
Lines
DNA fragments spanning2000 bp immediately upstream of the
translational start site of the 3 selected gametocyte-specific
markers were amplified from 3D7 genomic DNA template using
primer pairs PF14_0744-s CctcgaggtcgacGTACAATCGTTATAT-
TTG, PF14_0744-as CggatccgcggccgcGGAAGGAGGTATCCC-
GATATTG, PF14_0748-s CctcgaggtcgacCTTCATAGAACCGCC
CTATAC, PF14_0748-as CggatccgcggccgcCCTCCTTGCTTCCT-
CTAC, PF10_0164-s CctcgaggtcgacGCATGAACGTTTTGTA
AAC, and PF10_0164-as CggatccgcggccgcGTCGGAAATCGG
ATAAGAAG and were subcloned into the XhoI and BamHI sites
in pGEM7z. After sequence confirmation, fragments were ligated
into the SalI and NotI sites of the P. falciparum expression plasmid
pHHK(-)-green fluorescent protein (GFP) [6] by replacing the
HSP86 promoter upstream of the KAHRP signal sequence fused
to green fluorescent protein (GFP). The resulting expression
vectors pH744K(-)-GFP, pH748K(-)-GFP and pH164K(-)-GFP
were transfected into highly synchronized 5% ring stage
parasites of the P2G12 clone and selected using 10 nM WR99210
(kindly provided by Jacobus Pharmaceuticals), as described
elsewhere [7].
Fluorescence Microscopy Analysis of Transgenic Lines
The stage-specific GFP expression pattern in the 3 transgenic
lines 744/GFP, 748/GFP, and 164/GFP was analyzed using an
inverted epifluorescence microscope (Zeiss). Immunofluores-
cence assays were performed in fixed cells using a mixture of 4%
paraformaldehyde and 0.0075% glutaraldehyde, permeabilized
with 0.1% Triton X - 100, as described elsewhere [8]. This gentle
fixation method preserves GFP fluorescence and at the same
time allows antibody binding. For colocalization experiments,
we used polyclonal mouse antibodies against Pfs16 (1/5000).
Parasite nuclei were labeled with DAPI and analyzed in
mounting solution (Vectashield).
Flow Cytometry
Cytometry data were collected with a Beckman Coulter Cell
Lab Quanta SC Flow Cytometry System with 2 different
sources of excitation wavelength, a 488-nm laser and an ul-
traviolet (UV) light source optimized for excitation at 355/37
nm. The following band pass filters were used: 465/30 nm for
the UV channel and 525 nm for the fluorescein isothiocyanate
(FITC) channel. Initial gating in the UV channel for quantifi-
cation of the parasite load was performed with unstained,
uninfected RBCs incubated for the entire assay period. For this
purpose, the nuclear dye Hoechst 33342 (Invitrogen) was ti-
trated to a final concentration of 4 lmol/L. At this concen-
tration, single (rings and gametocytes) and multinucleated
parasites (trophozoites and schizonts) can be differentiated,
whereas the background is minimal (see also Figure 3). Gating
in the FITC channel for the quantification of gametocytemia
was performed with fresh, uninfected RBCs (uRBCs) and
uRBCs incubated for the entire assay period. The minimal
autofluorescence present in fresh uRBCs thereby provided
a clean control for initial gating (see also Figure 3). The used
voltage settings are 6.17 for Hoechst detection and 5.68 for GFP
detection. Data were collected with an acquisition of 50,000
events (Hoechst readout) and 400,000 events (GFP readout)
per sample. Raw flow cytometry (FCM) data were processed
with Quanta software and analyzed for half maximal inhibitory
concentration (IC50) calculations using GraphPad Prism.
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Definition of Assay Parameters
For the calculation of signal-to-noise ratios, uRBCs and the
RBCs infected with the parental P2G12 line were used as po-
tential negative controls. P2G12 was seeded into 96 well plates
and induced simultaneously with the positive control 164/GFP.
Signal to noise ratios were calculated as the ratio of 164/GFP
signal at day 2 divided by the uRBC or P2G12 signal from the
FITC channel at each time point during the assay period. The
sensitivity of microscopy and FCM to quantify parasitemia and
gametocytemia in serial dilutions was compared as follows. 164/
GFP-infected erythrocytes were seeded at 1% parasitemia in
a 96-well plate (without drug) and handled as described below
for the drug assay. On the day of analysis, these positive control
wells were pooled and stained with 4 lmol/L Hoechst. The in-
fected RBCs were subsequently diluted with uninfected RBCs in
a one-sixth serial dilution. Each data point of 3 independent
experiments was prepared in duplicates and analyzed in parallel
by FCM (GFP and Hoechst) as well as fluorescence microscopy
(GFP and Giemsa). The microscopy counting was performed
blinded. The resulting measured parasite and gametocyte levels
were plotted against the calculated values of the serial dilution
and analyzed with GraphPad Prism (San Diego, CA) for cor-
responding R square values.
Drug Assays
Highly synchronous 3–4-h old ring–stage parasites were seeded
at 1% parasitemia and 4% hematocrit in 110 lL of medium into
flat-bottom 96-well plates (Microtest Tissue Culture Plates;
Becton Dickinson). Twenty-four hours later, the culture me-
dium was increased to 220 lL to trigger sexual conversion by
a decrease in the hematocrit level from 4% to 2%. Serial dilu-
tions of compounds were either added at this point of the assay
(compound incubation period, 72 h) or 24 h later (incubation
period, 48 h). Compounds were dissolved in dimethyl sulfoxide
(DMSO), with the exception of chloroquine and methylene
blue, which were dissolved in water. DMSO alone was also tested
to account for possible DMSO-specific effects. The final con-
centration of DMSO ranged from 0.3% (Primaquine) to
0.002%, depending on the concentration of the used drug stock.
For each compound, 2 separate experiments were performed.
On the day of analysis, cells were incubated for 20 min at 37C
with the permeable nuclear dye Hoechst 33342 at a final con-
centration of 4 lmol/L.
RESULTS
Generation of Transgenic Parasites Expressing a Fluorescent
Reporter Only in Gametocytes
There is great variability between different in vitro adapted cell
lines in their capability to produce transmission stages. We
screened individual clones of the reference strain 3D7 to identify
parasites that are capable of sexual conversion (data not shown).
Several gametocyte-producing clones were identified, and one of
those, here termed P2G12, was selected for further studies. We
introduced a reporter gene into the P2G12 background for
quantification of sexual conversion and early gametocyte de-
velopment in live cells. The morphological differentiation as-
sociated with sexual development allows identification of
gametocytes only after 36 h of development. Parasites in earlier
stages can only be distinguished from asexual parasites using
specific antibodies, precluding studies with live parasites. To
establish unambiguous identification of early gametocyte stages
in live cells, we generated a series of transgenic parasite lines
expressing a fluorescent reporter under a gametocyte-specific
promoter. Several global transcriptional analyses have identi-
fied and validated markers of early sexual development in
P. falciparum [9–11]. We amplified 2000 bp of the upstream
regions of 3 such markers (PF14_0744 [9], PF14_0748 [9], and
PF10_0164 [10]), cloned them into a P. falciparum GFP ex-
pression vector, and transfected the P2G12 line with each of
these plasmids (Figure 1A), generating parasite lines 744/GFP,
748/GFP, and 164/GFP, respectively. Live fluorescence micros-
copy experiments demonstrate that GFP is expressed in these
lines during sexual development. These experiments also dem-
onstrated an expression peak at stage I for 744/GFP (Figure 1B)
and 748/GFP (Figure 1B) and at stage II or later for 164/GFP
(Figure 1C). We selected the 164/GFP line for additional analysis
and confirmed that the stage specificity of GFP expression
matched that of the transmission stage marker Pfs16 using
specific antibodies for detection (Figure 1D).
Establishment of a Gametocyte Induction Protocol With High-
Throughput Capacity
The 164/GFP line was used to develop a gametocyte induction
protocol that provides a high-throughput readout by flow cy-
tometry. Sexual conversion can be induced in vitro by a sudden
decrease in hematocrit concentration and a high parasite load,
reflecting conditions of physiological stress in the human host
that are known to correlate with increased numbers of trans-
mission stages in the blood circulation [12]. However, conver-
sion rates can vary widely between experiments. We aimed to
reduce this variation and increase reproducibility by starting
with a highly synchronized parasite culture, using more defined
media components, and optimizing the sexual conversion pro-
tocol. In a series of experiments, we altered individual param-
eters of the original protocol and quantified the increase in total
parasite load and sexual stages over time by live fluorescence
microscopy. First, we replaced human serum, a standard com-
ponent of the culture medium in current gametocyte induction
protocols [13, 14], with a lipid-rich bovine serum albumin
concentrate (AlbuMAX II) that is commonly used for asexual
parasite culture [15]. We determined that a concentration of 1%
AlbuMAX (w/v; compared with 0.5% for asexual culture) in the
complete medium results in sexual conversion rates superior to
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human serum without negatively affecting asexual growth
rates (Figure S1A). We then evaluated different starting parasite
loads to unlink anemia and high parasite loads as combined
triggers of sexual conversion, and reduce between-assay vari-
ability (Figure S1B). We also varied the time point of the
decrease in hematocrit concentration on the sexual conversion
rate to optimize the signal-to-background ratio. The final assay
protocol is shown in Figure 2.
Quantification of Sexual Conversion by Flow Cytometry
To make this protocol compatible for a high-throughput screen
we established conditions for cytometry-based quantification of
parasite and gametocyte loads (Figure 3). To quantify parasite
loads in live cells by flow cytometry, we took advantage of the
fact that mature RBCs lack a nucleus. Incubation with a mem-
brane-permeable DNA dye, such as Hoechst 33342, therefore
stains only parasite-infected erythrocytes [16]. Hoechst labeling
as quantified by UV fluorescence intensity correlates with the
number of nuclei per infected RBC and therefore allows dif-
ferentiation between individual parasite stages (Figure 3,
upper panel). Rings, early trophozoites, and gametocytes have 1
nucleus, whereas parasites in later asexual stages are undergoing
mitosis and have up to 16 nuclei. The number of sexual stages
was determined with the FITC channel to detect GFP
fluorescence. To establish a negative control for assay purposes,
we incubated uRBCs for the entire assay period. Although there
is virtually no background in the UV channel, we observed
significant background in the FITC channel (Figure 3, lower
panel). Autofluorescence of RBCs is due to oxidative damage,
hemoglobin degradation, and hemozoin formation in the
infected RBC [17]. To define the negative control for GFP
detection, we quantified fluorescence levels of uRBCs and
P2G12-infected RBCs during the assay period and calculated
signal–to-noise ratios (Figure 4A). These experiments demon-
strated that uRBCs incubated for the entire assay period are the
proper negative control for the assay. On the basis of this neg-
ative control, the z-factor (6 standard deviation) [18] for
Hoechst was determined to be 0.77 6 0.01, and for GFP, it was
0.24 6 0.03. To determine whether FCM quantification pro-
vides readout directly proportional to parasite growth and sex-
ual conversion, we compared total parasite and gametocyte
loads with microscopy counts (Figure 4B). Although total par-
asite counts correlated well during the entire assay period, the
FITC channel only detects significant numbers of gametocytes at
day 2. Stratifying the corresponding microscopy counts by stage
revealed that FCM only detects stage II parasites, which repre-
sent the vast majority of counts at day 2 (Figure 4B). Earlier
stages are not detected above the negative control, presumably
Figure 1. Characterization of transgenic parasite lines expressing GFP under different gametocyte-specific promoters. A-C, GFP expression during
sexual development. Transgenic parasites were cultured in T75 flasks, induced for in vitro sexual development by reduction of hematocrit as described
elsewhere [13], and analyzed live by fluorescence microscopy. Morphological differentiation of individual gametocyte stages (stage I–V) was based on the
classification by Hawking et al [43]. GFP was expressed throughout sexual development starting at sexually committed schizont stages. In 744/GFP
(A) and 748/GFP (B), fluorescence peaks during early development. In 164/GFP (C), fluorescence intensity increases during development, either through
elevated expression levels and/or accumulation of GFP over time. Stage I gametocytes are indistinguishable from asexual trophozoites except for the
presence of dispersed hemozoin crystals in the former. Stage II gametocytes adopt a characteristic morphology, with an elongated wheat-shaped body
and subpellicular extensions. SI/SII, gametocyte stage I and II. D, Co-localization of GFP fluorescence in 164/GFP with a transmission stage marker. To
determine whether GFP expression was indeed gametocyte specific, we performed immunofluorescence assay in induced cultures using antibodies
against the sexual stage antigen Pfs16 for co-localization. Two representative panels are shown (D), with a stage I gametocyte (top) and a stage III
gametocyte (bottom).
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due to the relatively weak GFP fluorescence (see also Figure 1C).
Serial dilutions of infected red blood cells (iRBC) at day 2 of the
assay demonstrated a linear relationship within the range of the
assay between both stage II numbers and total parasite loads as
determined by microscopy compared with FCM (Figure 4C).
Importantly, sexual conversion rates did not decrease during the
course of assay establishment and validation (Figure 4D), sug-
gesting that the P2G12 clone and the transgenic versions thereof
(eg, 164/GFP) harbor a stable genotype with respect to their
capability to produce gametocytes.
Assay Validation With a Set of Known Antimalarial Compounds
The assay was validated by determining IC50 concentrations for
some of the main antimalarial compounds that are currently in
use. These are chloroquine and mefloquine (which are quinine
based), 8-aminoquinolines (primaquine), and dihy-
droartemisinin, as well as the hydroxynaphthoquinone atova-
quone, the phenothiazin dye methylene blue, and the
antimicrobial biocide triclosan for comparison. To differentiate
the effect of the drug against asexual stages, sexual conversion
and early sexual stages, we used 2 different protocols for each
experiment. Specifically, drugs were added either when the he-
matocrit was reduced at the late trophozoite stage (day -1) or
24 h later at the early ring stage (day 0). As shown in Table 1,
IC50 values against asexual stages are in the same range as those
from previous assays using either a hypoxanthine incorporation
assay or cytometric assays with nuclear dyes [19–21]. However,
we noted that IC50 values were generally higher when drugs are
added at day 0 compared with drug addition at day -1. At least
part of this reduced susceptibility is probably due the inoculum
effect, which refers to an increase in the amount of drug nec-
essary to inhibit growth in the presence of higher numbers of
parasites [22]. Importantly, we provide the first experimental
Figure 2. Assay protocol in 96-well plates. Parasites were first treated
with sorbitol to obtain a loosely synchronous ring stage population. After
1 cycle, sequential purification of late stages on a Percoll gradient and
treatment with sorbitol 3 h later, after reinvasion, resulted in a highly
synchronous population of ring-stage parasites. These were seeded at
1% parasitemia and 4% hematocrit into a 96-well plate. After 24 h, the
hematocrit was reduced to 2% (ie, sexual conversion induced) by doubling
the volume of culture medium from 110 lL to 220 lL. After another 72 h
and 1 asexual replication cycle, cells from each well were analyzed to
quantify total parasite and gametocyte loads. The timeline represents the
assay period (96 h) performed in 96-well plates.
Figure 3. Establishment of Hoechst and GFP detection by cytometry. Upper panel, Hoechst staining of infected red blood cells (iRBCs) at day 2 of the
assay demonstrates that the majority of parasites have 1 nucleus (ie, rings and gametocytes [R 1 G]), whereas a subset is multinucleated (trophozoites
and schizonts [T1 S]). Both fresh uninfected red blood cells (uRBCs; from 4C) and uRBCs incubated along for the assay period and stained with Hoechst
were used as a negative control for gating. Lower panel, iRBCs at day 2 of the assay show GFP–positive population. This population is significantly higher
than the background signal represented by autofluorescence in uRBC control samples that were either fresh or were incubated for the entire assay
period.
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evidence that the quinine-based drugs as well as arteminisin are
equally effective against asexual stages and early sexual stages
(Table 1 and Figure 5A and B). Because these drugs
(ie, artemisinin, chloroquine, and mefloquine) showed a similar
effect on sexual stages when added either at day -1 or at day 0, it
is likely that early sexual development rather than conversion is
Figure 4. Definition of assay parameters. A, Signal-to-noise ratios using uninfected red blood cells (uRBCs) and the parental P2G12 line as potential
negative controls. Signal-to-noise ratios were calculated described in Materials and Methods. The ratio drops from 30-fold (when using cells from day -1
as negative control) to 5-fold (when using cells from day 2). Each data point represents at least 3 biological replicates done with technical duplicates.
B, Comparison of microscopy and flow cytometry (FCM) for the quantification of parasite and gametocyte loads. An increase in parasite concentration
from initially 1% to 18% during the assay period of 96 h is detected both by counting Giemsa-stained blood smears (circles, black solid line) and by
quantifying a Hoechst-stained sample of the same culture by FCM (cubes, black dashed line). Sexual stages, defined as the GFP-positive subpopulation of
infected red blood cells, increased from background levels of 0.005% to 0.15% at day 2, representing a 30-fold absolute or 5-fold relative increase
(correcting for replication rate). FCM detects only GFP expression of stage II gametocytes (cubes, green dashed line), whereas the weaker fluorescence of
earlier stages (ie, the sexually committed ring and stage I; termed Pre-Stage II in the graph) is only detectable by microscopy (triangle, solid blue). Stage II
gametocyte numbers quantified by microscopy (circles, solid green line) correlate well with GFP-positive cells determined by FCM. Each data point
represents at least 3 biological replicates done with technical triplicates. The graphs show mean values of the experiments, whereas the error bars
represent the standard error of the mean. C, Sensitivity of microscopy and FCM to quantify parasite load (left panel) and gametocyte load (right panel).
Each data point was prepared in duplicates as described in Materials and Methods and analyzed in parallel by FCM (GFP and Hoechst) as well as
fluorescence microscopy (GFP and Giemsa). The resulting measured parasite and gametocyte loads were plotted against the calculated values of the
serial dilution. The corresponding R2 values are as follows: 0.9659 by microscopy and 0.9798 by FCM for parasite load; 0.8345 by microscopy and 0.9610
by FCM for gametocyte load. D, The transgenic parasite line 164/GFP shows no loss of sexual conversion during continuous culture. The box-and-whisker
plot represents all assay positive control wells over the time period when drug assays were performed. The sample sizes are as follows: month 0.5,
n 5 16; month 1, n 5 18; month 3, n 5 36; month 3.5, n 5 22; month 4, n 5 32; month 4.5, n 5 39; month 5, n 5 29; month 5.5, n 5 45; month 6,
n 5 48; and month 6.5, n 5 24. No experiments were performed in months 1.5–2.5.
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targeted. Functional and morphological similarities of early
gametocytes with asexual stage parasites suggest that the effect of
these drugs is due to the same mechanism through which they
target asexual stages. Other compounds were significantly less
active or ineffective against early sexual–stage parasites. For
example, the presence of atovaquone or methylene blue, par-
ticularly at sublethal doses, appeared to increase sexual con-
version rates (Table 1 and Figure 5C and D). This supports
the hypothesis that activation of a stress response, either drug or
host induced, is linked to sexual conversion [23–25]. Prima-
quine, on the other hand, is known to be highly active against
hypnozoites and liver-stage schizonts in Plasmodium vivax and
Plasmodium ovale, as well as gametocytes of all the 4 human
malaria species [4]. However, primaquine is inactive under in
vitro conditions while transformed to an active metabolite in the
mammalian host [26].
DISCUSSION
The goal of eliminating and eventually eradicating human ma-
laria will only be possible if the transmission cycle can success-
fully be interrupted. This requires radical cure in symptomatic
patients and mass drug administration to eliminate multiple
stages of the parasite on a population level [27, 28]. The only
available compounds that are known to efficiently eliminate all
gametocyte stages are 8-aminoquinolines, including primaquine
and tafenoquine. However, they can cause hemolytic anemia in
people with glucose-6-phosphate dehydrogenase deficiency
[29]. It is therefore critical to develop a new generation of drugs
with favorable toxicity profiles that specifically target malaria
transmission stages. The recent establishment of cell-based high-
throughput screens that quantify the effect of compounds on
asexual parasite proliferation in RBCs has opened new avenues
for drug development against human malaria [20, 30]. More-
over, the widespread application of transfection technology in
the malaria field provides the basis for a next generation of cell-
based assays targeting specific pathways or life cycle stages. We
have established a reproducible sexual conversion protocol using
a transgenic Plasmodium strain with a high and stable degree of
conversion to gametocytes that expresses a gametocyte-specific
reporter.
Table 1. Half Maximal Inhibitory Concentration (IC50) Values Representing the Effect of All Antimalarials Tested on Gametocytes and
Parasitemia
Drug addition
Asexual stages Sexual stages
Antimalarial classs Compound Day -1 Day 0 Day -1 Day 0
IC50 Pub. IC50 IC50 IC50 or effect IC50 or effect
Quinoline-containing drugs Chloroquine 20 6 8.5 10-30 40.4 6 10.7 31 6 5.8 42.2 6 13.5
Mefloquine 36.3 6 11.6 50 80 6 24.8 42.4 6 23.9 94.8 6 34.8
Artemisinins DHA 6.4 6 1.3 0.8–3 28.9 6 2.6 10.2 6 2.3 26.3 6 9.9
Naphthalenes Atovaquone 1.8 6 0.2 0.9–3 1.66 6 0.5 Proinducing
(188% at 15 nM)
Slight reduction
8-Aminoquinolinea Primaquine 10.7 6 4.8 15 30.5 6 17.6 No effect No effect
Phenothiazine dye Methylene blue 16.5 6 3.5 4 24.1 6 7.4 Proinducing
(276% at 125 nM)
Proinducing
(338% at 31 nM)
Antibiotic or antifungala Triclosan 5.3 6 0.7 1.1 7.6 6 0.7 4 6 2.1 7.5 6 4.7
NOTE. IC50 values are in nM, unless otherwise indicated. Each data point represents at least 3 biological replicates done in technical duplicates. Published IC50
data for comparison are derived from [19, 20, 44]. The data are represented as mean values (6 standard deviation) for the biological replicates. The term ‘‘slight
reduction’’ indicates minor reduction in gametocyte load, which is not sufficient to determine classic IC50 curves.
a IC50 values are in lM.
Figure 5. Half maximal inhibitory concentration curves representing the
effect of chloroquine (A), DHA (B), atovaquone (C), and methylene dlue (D)
on gametocyte and parasite loads. Each assay represents at least 3
biological replicates with 2 technical replicates per plate. The graphs
show mean values of the experiments, whereas the error bars represent
the standard error of the mean. conc., concentration.
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The observed differential in vitro activity against early ga-
metocyte stages confirms data from field studies: for susceptible
parasites, treatment with artemsinin and derivatives as well as
chloroquine significantly reduces the prevalence and density of
malaria transmission stages [31–34]. Emergence of resistance,
however, is usually paralleled by increased transmission rates
[35]. This is likely due to both selection on a genetic level and
increased conversion rates at sublethal drug concentrations.
Altogether, an initial screen of known antimalarials demon-
strates that we have met the 2 main goals of this study: (1) we
established a high-throughput screen that performs as well as
published screen formats in quantifying the impact of drugs on
asexual parasite growth, and (2) the same assay allows highly
reproducible quantification of specific drug effects on sexual
conversion and early sexual development.
To our knowledge this is the first targeted cell-based high
throughput assay in a eukaryotic pathogen. It may serve as
a template for the development of similar assays targeting
either particular cellular pathways or differentiation processes
for drug development purposes in human pathogens, such as
Toxoplasma, Trypanosoma, and Leishmania species. In ma-
laria, the assay will finally provide a basis for the development
of drugs that are specifically targeted toward blocking the
development of transmission stages. Because the fluorescent
reporter is expressed throughout sexual development, it will
be possible to perform secondary assays that quantify the
effect of candidate compounds on the transmission-competent
mature gametocytes. Identification of compounds that modulate
sexual conversion will also provide biological probes to perform
mechanistic studies on this important step in the parasite cycle,
which is least understood. Several candidate pathways have been
implicated in determining sexual conversion rates, however,
a small-scale screen of activators and inhibitors of G protein-
coupled receptor (GPCR)-dependent signaling could not
confirm previous reports of an involvement of this pathway in
conversion [36–42] (Figure S1C). Considering that current
antimalarials have a very limited range of cellular targets, we
anticipate that a large-scale high-throughput screen with
structurally diverse small-molecule libraries have the potential
to uncover a wealth of novel chemotypes and targets for future
intervention strategies.
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